CL2012001186A1 - Peptido fosforilado o sal farmaceuticamente aceptable del mismo que activa la guanilato ciclasa c en el sistema gastrointestinal superior; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno gastrointestinal. - Google Patents

Peptido fosforilado o sal farmaceuticamente aceptable del mismo que activa la guanilato ciclasa c en el sistema gastrointestinal superior; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno gastrointestinal.

Info

Publication number
CL2012001186A1
CL2012001186A1 CL2012001186A CL2012001186A CL2012001186A1 CL 2012001186 A1 CL2012001186 A1 CL 2012001186A1 CL 2012001186 A CL2012001186 A CL 2012001186A CL 2012001186 A CL2012001186 A CL 2012001186A CL 2012001186 A1 CL2012001186 A1 CL 2012001186A1
Authority
CL
Chile
Prior art keywords
treat
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
guanylate cyclase
Prior art date
Application number
CL2012001186A
Other languages
English (en)
Spanish (es)
Inventor
Angelika Fretzen
Mark G Currie
Marco Kessler
Daniel P Zimmer
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001186(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of CL2012001186A1 publication Critical patent/CL2012001186A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
CL2012001186A 2009-11-09 2012-05-07 Peptido fosforilado o sal farmaceuticamente aceptable del mismo que activa la guanilato ciclasa c en el sistema gastrointestinal superior; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno gastrointestinal. CL2012001186A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25926409P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
CL2012001186A1 true CL2012001186A1 (es) 2013-07-12

Family

ID=43503086

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001186A CL2012001186A1 (es) 2009-11-09 2012-05-07 Peptido fosforilado o sal farmaceuticamente aceptable del mismo que activa la guanilato ciclasa c en el sistema gastrointestinal superior; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno gastrointestinal.

Country Status (26)

Country Link
US (3) US20140179607A9 (cg-RX-API-DMAC7.html)
EP (1) EP2499154B1 (cg-RX-API-DMAC7.html)
JP (1) JP5913115B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120115495A (cg-RX-API-DMAC7.html)
CN (1) CN102812038B (cg-RX-API-DMAC7.html)
AR (1) AR078950A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010314866B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012011730A2 (cg-RX-API-DMAC7.html)
CA (1) CA2779482A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012001186A1 (cg-RX-API-DMAC7.html)
CO (1) CO6551683A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120303A (cg-RX-API-DMAC7.html)
EA (1) EA022817B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011962A (cg-RX-API-DMAC7.html)
ES (1) ES2620153T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20166435B (cg-RX-API-DMAC7.html)
IL (1) IL219596A0 (cg-RX-API-DMAC7.html)
MX (2) MX350046B (cg-RX-API-DMAC7.html)
NZ (1) NZ599751A (cg-RX-API-DMAC7.html)
PH (1) PH12012500916B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201407403UA (cg-RX-API-DMAC7.html)
TW (1) TWI482626B (cg-RX-API-DMAC7.html)
UA (1) UA114274C2 (cg-RX-API-DMAC7.html)
UY (2) UY33018A (cg-RX-API-DMAC7.html)
WO (1) WO2011057272A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201203342B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2012510518A (ja) * 2008-12-02 2012-05-10 アイロンウッド ファーマシューティカルズ，インコーポレーテッド 体液貯留障害を処置するための方法および組成物
GEP20166435B (en) * 2009-11-09 2016-02-25 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
CN102822194B (zh) * 2009-12-07 2016-10-26 硬木药品公司 用于胃肠病症的治疗
CA2835624A1 (en) * 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US20160213739A1 (en) * 2011-05-11 2016-07-28 Ironwood Pharmaceuticals, Inc Treatments for disorders using guanylate cyclase c agonists
WO2012170804A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MX347354B (es) * 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2016015055A1 (en) * 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Colon cleansing compositions
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB290795A (en) 1927-04-08 1928-05-24 British Colour Printing Compan Improvements in or relating to advertising or display devices
US5962220A (en) 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
DE69433564T2 (de) 1993-10-26 2004-12-23 Thomas Jefferson University Verbindungen, die kolorektale Krebszellen spezifisch binden, und Verfahren zu ihrer Verwendung
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO2001080871A2 (de) * 2000-04-22 2001-11-01 Ipf Pharmaceuticals Gmbh Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2
DK1594517T3 (da) 2003-01-28 2007-10-29 Microbia Inc Sammensætninger til behandlingen af gastrointestinale lidelser
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2619650A1 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2559319T3 (es) * 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
SG193801A1 (en) 2008-08-15 2013-10-30 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
GEP20166435B (en) * 2009-11-09 2016-02-25 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
US8748575B2 (en) 2010-06-09 2014-06-10 Combimab, Inc. Therapeutic peptides

Also Published As

Publication number Publication date
CA2779482A1 (en) 2011-05-12
CO6551683A2 (es) 2012-10-31
AR078950A1 (es) 2011-12-14
TWI482626B (zh) 2015-05-01
IL219596A0 (en) 2012-06-28
SG10201407403UA (en) 2014-12-30
PH12012500916B1 (en) 2018-03-23
AU2010314866A1 (en) 2012-05-31
JP2013510182A (ja) 2013-03-21
KR20120115495A (ko) 2012-10-18
UY33017A (es) 2011-06-30
WO2011057272A1 (en) 2011-05-12
EA201290322A1 (ru) 2013-01-30
US20130085107A1 (en) 2013-04-04
MX350046B (es) 2017-08-24
EP2499154A1 (en) 2012-09-19
ES2620153T3 (es) 2017-06-27
US20110118184A1 (en) 2011-05-19
CN102812038B (zh) 2016-05-18
MX2012005368A (es) 2012-06-13
UA114274C2 (uk) 2017-05-25
CN102812038A (zh) 2012-12-05
US8946158B2 (en) 2015-02-03
EA022817B1 (ru) 2016-03-31
US20140024593A1 (en) 2014-01-23
BR112012011730A2 (pt) 2016-03-08
JP5913115B2 (ja) 2016-05-11
TW201116291A (en) 2011-05-16
NZ599751A (en) 2014-08-29
US8507447B2 (en) 2013-08-13
GEP20166435B (en) 2016-02-25
ECSP12011962A (es) 2012-07-31
UY33018A (es) 2011-01-31
ZA201203342B (en) 2013-01-30
CR20120303A (es) 2012-08-08
EP2499154B1 (en) 2016-12-21
PH12012500916A1 (en) 2018-01-29
AU2010314866B2 (en) 2014-10-30
US20140179607A9 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CL2012001186A1 (es) Peptido fosforilado o sal farmaceuticamente aceptable del mismo que activa la guanilato ciclasa c en el sistema gastrointestinal superior; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno gastrointestinal.
MX2013013276A (es) Formas de dosificacion farmaceuticas intranasales que comprenden naloxona.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2007003352A1 (es) Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen
AR082688A1 (es) Uso de aglomerantes para preparar formulaciones estables al almacenamiento
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
CL2014003421A1 (es) Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008000510A1 (es) Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
CL2007003303A1 (es) Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2013001943A1 (es) Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.
BRPI1013763A2 (pt) Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
CL2015001708A1 (es) Polipétido que comprende el factor de crecimiento tipo insulina 1 (igf-1), donde el aminoácido glicina en posición 42 es suprimido o mutado; polinucléotido; composición farmacéutica que lo comprende; y uso para tratar un trastorno muscular, enefermedad pulmonar obstructiva o enfermedad crónica de riñón.
CR11418A (es) Trans-clomifeno para el sindrome metabolico
CL2008000254A1 (es) Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer.
CL2012002437A1 (es) Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos.
CL2014003167A1 (es) Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2013003377A1 (es) Conjugado polipeptídico que comprende un componente polipeptídico covalentemente unido a una fracción que aumenta la duración; composición farmacéutica que comprende un conjugado polipeptídico; método para tratar una enfermedad o desorden en un sujeto.
CL2013002905A1 (es) Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.